Optimized Structured Treatment Interruption for HIV Therapy and Its Performance Analysis on Controllability |
Ko Ji Hyun
(Drexel University 의용생체공학부)
Kim Won Hee (한양대학교 전자전기컴퓨터공학부) Chung Han Byul (한양대학교 전자전기컴퓨터공학부) Chung Chung Choo (한양대학교 전자전기컴퓨터공학부) |
1 | R. Zurakowski, A. R. Teel, and D. Wodarz, 'Utilizing alternate target cells in treating HIV infection through scheduled treatment interruptions,' American Control Conference, Boston, pp. 946-951, June 2004 |
2 | S. Kubiak, H. Lehr, R. Levy, T. Moeller, A. Parker, E. Swin, 'Modeling control of HIV infection through structured treatment interruptions with recommendations for experimental protocol,' CRSC Technical Report (CRSC-TR01-27). 2001. (Also at http://www.math.montana.edu/parker.) |
3 | A. Schwartz, 'Theory and implementation of numerical methods based on Runge-Kutta integration for solving optimal control problems,' Ph.D Dissertation, Univ. of California, Berkeley, 1996 |
4 | D. E. Kirk, 'Optimal Control Theory: An Introduction,' Prentice Hall,1970 |
5 | D. Wodarz, 'Helper-dependent vs. helper-independent CTL responses in HIV infection: implications for drug therapy and resistance,' J. Theor. Biol., vol. 213, pp. 447-459, August 2001 DOI ScienceOn |
6 | D. Q. Mayne, J. B. Rawlings, C. V. Rao and P. O. M. Scokaert, 'Constrained model predictive control: Stability and optimality,' Automatica, vol. 36, pp. 789-814, 2000 DOI ScienceOn |
7 | J. M. Lee and J. H. Lee, 'Approximate dynamic programming strategies and their applicability for process control: A review and and future directions,' submitted to International Journal of Control, Automation and Systems, May 2004 |
8 | R. F. Stengel, R. Ghigliazza, N. Kulkami and O. Laplace, 'Optimal control of innate immune response,' Optimal Control Applications and Methods, vol. 23, pp. 91-104, January 2002 DOI ScienceOn |
9 | M. E. Brandt and G. Chen, 'Feedback control of a biodynamical model of HIV-l,' IEEE Trans. on Biomedical Engineering, vol. 48,pp.754-759,July 2001 DOI ScienceOn |
10 | J. J. Kutch and P. Gurfil, 'Optimal control of HIV infection with acontinuously-mutating viral population,' Proceedings of the American Control Conference, vol 5, pp. 4033-4038, Anchorage, May 2002 |
11 | J. A. M. Felippe de Souza, M. A. L. Caetano and T. Yoneyama, 'Analysis of a sub-optimal scheme of drug dosage in the AIDS treatment,' In proceedings of American Control Conference, pp. 1188-1193, Denver, Colorado, June 2003 |
12 | R. Zurakowski and A. R. Teel, 'Enhancing immune response to HIV infection using MPC-based treatment scheduling,' American Control Conference, Denver, pp. 1182-1187, June 2003 |
13 | H. Shim, S. J. Han, C. C. Chung, S. W. Nam and J. H. Seo, 'Optimal scheduling of drug treatment for HlV infection: continuous dose control and receding horizon control,' International Journal of Control, Automation and Systems. vol. 1, no. 3, pp. 282-288, September 2003 |
14 | A. M. Jeffrey, X. Xia, and I. K. Craig, 'Controllability analysis of the chemotherapy of HlV/AIDS,' IFAC, 15th Triennial World Congress, Barcelona, Spain, 2002 |
15 | D. Wodarz and M. A. Nowak, 'Specific therapy regimes could lead to long-term immunological control of HIV,' PNAS, vol. 96, pp. 14464-14469, December 1999 DOI |
16 | A. M. Jeffrey, X. Xia, and I. K. Craig, 'When to inititate HIV therapy: a control theoretic approach,' IEEE Trans. On Biomedical Engineering, vol. 50, no 11, pp. 1213-1220, Nov. 2003 DOI ScienceOn |
17 | M. A. Nowak and R. M. May, 'Virus dynamics: mathematical principles of immunology and virology,' Oxford University Press, 2000 |
18 | J. S. James, 'Human retroviruses and related infections,' Major U.S. Scientific AIDS Conference, Feb. 1995. [Online]. Available: http://www.aids.org/atn/a-216-01.html |
19 | D. Wodarz and M. A. Nowak, 'Treatment interruptions,' factsheets, AIDS.org, April 2003. [Online] Available: http://www.aids.org/factSheets/406-Treatment -Interruptions.html |
20 | J. S. James, 'Treatment interruption; advanced HIV,' Dr. Cal Cohen Interview on Retroviruses Conference (part 2 of 2), April 2003. [Online] Available: http://www.aids.org/atn/a-390-01.html |
21 | R. F. Stengel, R. Ghigliazza, N. Kulkami and O. Laplace, 'Optimal control of a viral disease,' In proceedings of American Control Conference, vol. 5, pp. 3795-3800, June 2001 DOI |
22 | R. F. Stengel, R. Ghigliazza and N. Kulkami, 'Optimal enhancement of immune response,' Bioinformatics, vol. 18, pp. 1227-1235, March 2002 DOI ScienceOn |
23 | A. S. Perelson and P. W. Nelson, 'Mathematical analysis of HIV-1 dynamics in vivo,' SIAM, vol. 41, no. 1, pp. 3-44, 1999 DOI ScienceOn |
24 | S. Bonhoeffer, M. Rembiszewski, G. M. Ortiz, D. F. Nixon, 'Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection,' AIDS, vol. 14, pp. 2313-2322, 2000 DOI ScienceOn |
25 | C. A. Janeway, 'Immunobiology,' Garland Churchill Livingstone, 2001 |